Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glecaprevir/Pibrentasvir 8 weeks in treatment-naïve HCV with compensated cirrhosis
NCT03089944Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Apr 2017
- Primary completion
- Jul 2019
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 19
01
Overview
A Phase 3 trial of glecaprevir, pibrentasvir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Apr 2017; status: completed.
02
Drugs
glecaprevirpibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03089944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03089944.